Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02496039 · ClinicalTrials.gov registry record · Phase 4
Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)
A Phase 4 study, sponsored by Avanir Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT02496039: Clinical Trial Phase 4 study, sponsored by Avanir Pharmaceuticals.
NCT02496039 is a Phase 4 study that was terminated before completion, run by Avanir Pharmaceuticals. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02496039, a Phase 4 study, was terminated before completion, sponsored by Avanir Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
6 month study of NUEDEXTA ® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients.
Primary Outcome
The study was terminated prematurely because of difficulty with recruiting. Analysis for this outcome measure was not performed because data were not collected prior to termination.
Interventions
- DRUG NUEDEXTA®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-05 |
| Phase | Phase 4 |
Why NCT02496039 stopped before completion
NCT02496039 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which NUEDEXTA® is the first listed.
NCT02496039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02496039 about?
NCT02496039 is a clinical study titled "Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)". 6 month study of NUEDEXTA ® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients.
What is the current status of trial NCT02496039?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2015-09. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02496039?
The interventions under investigation include: NUEDEXTA® (DRUG).
Who is sponsoring clinical trial NCT02496039?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02496039's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia